Boston halts drug-eluting stent trial
This article was originally published in Clinica
Boston Scientific has halted the further enrolment of patients in a European clinical trial of a drug-coated coronary stent for reducing restenosis. The move comes after researchers reported an "unacceptable" rate of major adverse events in some of the patients implanted with the device.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.